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Allergic Conjunctivitis and Latent Infections
Raimondo Forte, MD,* Gilda Cennamo, MD,* Salvatore Del Prete, MD,†
Nicoletta Napolitano, MD,* Elvira Farese, MD,* and Antonio Del Prete, MD*
Purpose: The purpose of this study was to evaluate in a large series
the incidence of latent infection during chronic allergic conjunctivitis.
Methods: In a 5-year follow-up prospective, nonrandomized trial,
we evaluated 236 patients (472 eyes) with a history of allergic
conjunctivitis but without evidence of infection. Conjunctival
scrapings were examined cytologically, and antibiograms and
antimicrograms were assessed. The 472 eyes were divided into
5 subgroups based on the percent of eosinophilic cells in conjunctival
specimens.
Results: Latent concurrent infection was identified in 176 of 472
eyes (37%): Candida albicans (55.2%), Staphylococcus epidermidis
(50.9%), Chlamydia trachomatis (30.7%), and Staphylococcus
aureus (23%). The incidence of concurrent infection (mainly
bacterial infection) strongly correlated with the percent of eosino-
philic cells. Concurrent bacterial infection was identified in 26 of 26
cases of the subgroup with the highest percent of eosinophilic cells.
Conclusion: Chronic allergic conjunctivitis may be associated with
latent infection. Pathogens can stimulate activation of eosinophils
with a consequent worsening and chronicity of allergic symptoms.
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INTRODUCTION
Allergic conjunctivitis is defined as conjunctival
inflammation determined by an abnormal reaction to
antigenic stimulation.1,2 It is caused by genetic and environ-
mental factors (a higher incidence is associated with
a hot climate). There are 6 main forms of this condition:
seasonal allergic conjunctivitis, perennial allergic conjuncti-
vitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis,
giant papillary conjunctivitis, and contact or drug-induced
dermatoconjunctivitis.3
Allergic conjunctivitis may be the result of a type I
hypersensitivity reaction (which is immediate and involves
mainly IgE, ie, pollinosis conjunctivitis), a type IV hypersen-
sitivity reaction (delayed-type, cell-mediated), or a combina-
tion of both. In 2006, the International Ocular Inflammation
Society proposed a classification for conjunctivitis and
blepharitis. Ocular allergy was classified as a ‘‘noninfectious,
immunomediated’’ conjunctivitis. Seasonal allergic conjunc-
tivitis and perennial allergic conjunctivitis were included in the
‘‘IgE-mediated’’ group, whereas vernal keratoconjunctivitis
and atopic keratoconjunctivitis were included in the ‘‘non-
IgE-mediated’’ group. T-cells, macrophages, neutrophils, and
eosinophils play an important role in type IV allergic
inflammation.4 In particular, the concentration of eosinophils
is related to the degree of allergic inflammation.
The exact etiologic mechanisms of allergic conjuncti-
vitis and their possible correlations with pathogens are still
debated. IgE does not appear to be involved in contact lens
conjunctivitis,5 whereas a correlation between vernal kerato-
conjunctivitis and Chlamydia trachomatis has been identified
in atopic patients.6 In an attempt to shed light on this issue, we
evaluated the incidence of latent infections during chronic
allergic conjunctivitis in a large series of patients.
MATERIALS AND METHODS
In this prospective, nonrandomized trial, we evaluated
236 patients (472 eyes) seen in the Eye Department of the
University of Naples Federico II from 2003 to 2008 with
a diagnosis of chronic allergic conjunctivitis but without
clinical evidence of conjunctival infection. An allergic
etiology was diagnosed from a familial history of atopy,
clinical examination, Prick test, and identification of specific
IgE in tears and blood with the RAST technique.7,8 In 174
patients (73.7%), previous antiallergic topical and systemic
treatment and topical steroid treatment had been unsuccessful.
Topical or systemic anti-inflammatory or anti-infective
treatment was not allowed during the 2 weeks preceding our
study. Patients with any systemic or ocular disease were
excluded from the study. Patients with a nonurban lifestyle
were also excluded to reduce the risk of conjunctival
contamination from a rural environment.
The superior and inferior tarsal conjunctiva of each eye
was scraped with an Ayre spatula to collect samples for
cytologic examination. Specimens were fixed and stained with
May-Grumwald-Giemsa.9 Antibiograms and antimicrograms
were obtained to identify possible infection. Cultures were
confirmed positive based on neutrophil count to avoid false-
positive results from contamination. Direct immunofluorescence
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on conjunctival scrapings was used to identify C. trachomatis.
The conjunctival specimens of the 472 eyes were divided into
5 groups based on percent of eosinophilic cells: class 1, 0% to
1% eosinophilic cells; class 2, 2% to 4% eosinophilic cells;
class 3, 5% to 8% eosinophilic cells; class 4, 9% to 13%
eosinophilic cells; and class 5, 14% to 20% eosinophilic cells.
All procedures adhered to the tenets of the Declaration of
Helsinki and the protocol was approved by the Institutional
Review Board for Human Research of the University of
Naples Federico II. Statistical analysis was performed with
SPSS software (version 13.0; SPSS Inc., Chicago, IL).
Correlations between the classes of eosinophilia and type of
infection was evaluated with Pearson’s chi square coefficient
and Pearson’s correlation coefficient r. P, 0.05 was defined as
statistically significant.
RESULTS
The mean age of the 236 patients (83 females, 153
males) was 22 years (range, 7–32 years). One hundred forty-
five patients were affected by seasonal allergic conjunctivitis,
49 by perennial allergic conjunctivitis, 20 by atopic
conjunctivitis, and 22 by giant papillary conjunctivitis.
Concurrent infection was identified in 176 of the 472 eyes
(37%), and the pathogens are listed in Table 1. We detected
bacteria in 161 of the 176 eyes (91.4%) (Table 2), mycosis in
29 eyes (16.5%) (Table 3), and C. trachomatis in 54 eyes
(30.7%). Concurrent infection associated with a high neutro-
phil count was present in 58 of the 176 eyes (33%). There was
a strong correlation between the incidence of infections
and percent of eosinophilic cells (Pearson’s chi square test
14.05, P = 0.003) (Table 4). As shown in Table 5, infection was
identified in 44.8% and 60.5% of cases in eosinophilia classes
4 and 5, respectively. Interestingly, eosinophilia class was
correlated with risk of bacterial infection (Pearson’s correla-
tion coefficient r = 0.712, P = 0.003) (Table 6). In fact,
bacterial infections occurred in 96.5% of cases in class 3, in
91.4% of cases in class 4, and in 100% of cases in class 5.
DISCUSSION
In our series of 472 eyes, concurrent infection was
present in 176 eyes (37%), and in 161 cases (91.4%), it was the
result of bacteria. Bacterial infections were most often the
result of Staphylococcus epidermidis (82 of 161 cases
[50.9%]) and Staphylococcus aureus (37 of 161 cases
[23%]), mycotic infections were most often the result of
Candida albicans (16 of 29 cases [55.2%]), and there was
a high frequency of C. trachomatis infections (54 of 176
[30.7%]).
Severe corneal ulcers and keratitis secondary to fungal
and bacterial infection have been reported in cases of vernal
and atopic keratoconjunctivitis.10–13 The presence of a latent
infection could be the first step in the development of these
severe corneal complications.
S. aureus can be isolated from the lid margins of most
patients with atopic keratoconjunctivitis.14 S. epidermidis
normally inhabits the skin of humans and animals and mucous
membranes and is usually nonpathogenic.15 In our study, the
presence of S. epidermidis was considered an active infection
because of the high neutrophil count in the inflammatory
component of the conjunctival mucosa.16 C. trachomatis, an
obligate intracellular parasite, infects moist mucosal surfaces
where it produces covert damage principally by triggering
a localized cell-mediated immune response that is magnified
by repeated exposure to infection. C. trachomatis infection
during atopic conjunctivitis has already been reported.6,17 It
could be the result of the downregulation of the expression of
a wide spectrum of epithelial cell adhesion proteins and
TABLE 1. Number and Type of Pathogens Detected in 176
Eyes With Concurrent Infection During Chronic
Allergic Conjunctivitis
No. Eyes (%) Pathogen
97 (55.1) Bacteria
5 (2.8) Mycetae
16 (9) Chlamydia trachomatis
20 (11.4) Bacteria + Mycetae
34 (19) Bacteria + C. trachomatis
4 (2.3) Bacteria + C. trachomatis + Mycetae
TABLE 2. Subgroups of Bacteria Detected in 161 Eyes With
Bacterial Infection During Allergic Conjunctivitis
No. Eyes (%) Bacteria
82 (50.9) Staphylococcus epidermidis
37 (22.9) Staphylococcus aureus
8 (4.9) Staphylococcus albus
5 (3.1) Escherichia coli
4 (2.5) Staphylococcus haemoliticus
4 (2.5) Staphylococcus capitis
4 (2.5) Micrococcus luteus
3 (1.8) Staphylococcus saprophyticus
3 (1.8) Streptococcus viridans
2 (1.2) Enterobacter agglomerans
2 (1.2) Pseudomonas maltophilia
2 (1.2) Klebsiella pneumoniae
1 (0.6) Streptococcus haemoliticus
1 (0.6) Micrococcus spp
1 (0.6) Pseudomonas fluorescens
1 (0.6) Serratia marcescens
1 (0.6) Klebsiella oxytoca
TABLE 3. Subgroups of Mycetae Detected in 29 Eyes
Presenting Mycotic Infection During Allergic Conjunctivitis
No. Eyes (%) Mycetae
16 (55.1) Candida albicans
3 (10.3) Rhodotorula rubra
3 (10.3) Pityrosporum ovale
2 (6.9) Criptococcus albidens
2 (6.9) Tricosporon
2 (6.9) Cladosporium werneckii
1 (3.4) Candida kruzei
840 | www.corneajrnl.com q 2009 Lippincott Williams & Wilkins
Forte et al Cornea  Volume 28, Number 8, September 2009
cytoskeletal elements in the conjunctiva of patients with
seasonal allergic conjunctivitis.18
Various factors have been implicated in the development
of a bacterial infection in allergic patients, although a direct
relationship between allergy and infections has not been
shown. Prolonged steroid treatment has been reported to
increase bacterial and mycotic infections19,20 and was present
in the history of many patients (73.7%) enrolled in our study.
Furthermore, antihistamine therapy and sicca syndrome may
reduce tear secretion21 with a consequent weakening of
defense against pathogens. The antimicrobial effect of the tear
film may be impaired in allergic conjunctivitis because of
possible alterations of the immunoglobulin composition and
reduced levels of lactoferrin, an iron-complexing protein with
bacteriostatic properties. Conjunctival chemosis at the limbus
may affect the stability of the tear film. Finally, the corneal
epithelium may be damaged by the mechanical abrasion
exerted by giant papillae or punctate superficial keratitis
during allergic conjunctivitis22 with an increased risk of
infection.23
In our series, the incidence of concurrent infections was
related to the number of eosinophilic cells. In fact, the number
of eosinophils was greater in cases of bacterial infection
(bacteria were present in all cases with class 5 eosinophilia).
The phagocytic action of human eosinophils toward bacteria
has been shown by in vitro studies.24 Eosinophils can
inactivate such bacterial species as Escherichia coli, S. aureus
and Mycoplasma, and fungi,24–26 although it is not clear if they
are comparable to neutrophils in phagocytic and bactericidal
action24,27 or whether they are more efficiently triggered by
high or low numbers of bacteria.24,28 The bactericidal potential
of eosinophils arises from their ability to mount an oxidative
burst29,30 and to produce cytotoxic proteins from specific
granules located in the cytoplasm, namely, major basic protein,
eosinophil peroxidase, and eosinophil cationic protein.31,32
Eosinophils can produce powerful oxidants thanks to their rich
supply of NADPH oxidase molecules that generate superoxide
and H2O2,33,34 and these oxidants may act synergistically with
released granule proteins.35 It is possible that when eosinophils
come into contact with bacteria that have passed across leaky
mucosal membranes or damaged skin, eosinophilic activation
may perpetuate allergic inflammatory reactions. Bacterial
species that are among the most potent activators of
eosinophils (ie, E. coli, S. aureus, and Clostridium perfrin-
gens) have been implicated in the development of allergy
because their numbers are relatively increased in the intestinal
flora of infants destined to become allergic.36 A high rate of
Chlamydia infection associated with the presence of eosino-
phils has been reported during atopic conjunctivitis.6,37 It is
likely that in our series, activation of conjunctival eosinophils
by bacterial and mycotic pathogens may have elicited an
abnormal and prolonged allergic response.
In conclusion, in a patient presenting with chronic
allergic conjunctivitis, a latent infection may be present with
consequent worsening and chronicity of symptoms. Increased
levels of eosinophils are a consequence of infections and could
promote chronic allergic conjunctivitis. In these cases, a high
level of eosinophils could serve as a marker of concurrent
infection. Detection of latent infections seems advisable so as
to start prompt, targeted antibiotic therapy.
TABLE 5. Number and Type of Infections in Allergic Eyes in
the 5 Eosinophilic Classes*
Infections/Allergic
Eyes (%)
No.
Eyes Pathogen
Eosinophilic class 1 7 Bacteria
17/52 (32.7) 5 Chlamydia trachomatis
4 C. trachomatis + bacteria
1 Mycetae
Eosinophilic class 2 23 Bacteria
42/146 (28.8) 7 C. trachomatis
5 C. trachomatis + bacteria
4 Bacteria + Mycetae
3 Mycetae
Eosinophilic class 3 32 Bacteria
57/153 (37.2) 8 Bacteria + Mycetae
11 C. trachomatis +bacteria
3 C. trachomatis +bacteria + Mycetae
3 C. trachomatis
Eosinophilic class 4 20 Bacteria
35/78 (44.8) 8 C. trachomatis + bacteria
5 Bacteria + Mycetae
1 C. trachomatis
1 Mycetae
Eosinophilic class 5 16 Bacteria
26/43 (60.5) 7 C. trachomatis + bacteria
2 Bacteria + Mycetae
1 C. trachomatis + bacteria + Mycetae
*Pearson’s chi square test = 14.05, P = 0.003.
TABLE 6. One Hundred Seventy-six Eyes Affected by Allergic
Conjunctivitis and Bacterial Infection According to
Eosinophilic Class*
Eosinophilic Class
Cases of Bacterial
Infection (%)
1 11/17 (64.7)
2 32/42 (76.2)
3 55/57 (96.5)
4 32/35 (91.4)
5 26/26 (100)
*Pearson’s r = 0.712, P = 0.003.
TABLE 4. Number of Eyes in the 5 Eosinophilic Classes
Class Eosinophilic Cells Eyes
1 0–1% 52
2 2–4% 146
3 5–8% 153
4 9–13% 78
5 14–20% 43
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